Overview of Global Narcolepsy Drugs Market to 2026

DUBLIN, January 17, 2022 /PRNewswire/ — The “Narcolepsy Drugs Market – Global Industry Analysis (2018-2020) – Market Growth Trends and Forecast (2021-2026)” report has been added to from ResearchAndMarkets.com offer.

This report states that the Global Narcolepsy Drugs Market will reach a valuation of US$6,588 million by 2025 from US$3,875.1 million in 2021.

The demand for these drugs will increase due to improved diagnostics around the disease, which makes people excessively sleepy during the day. Although it is a relatively rare disorder, analysts predict that demand for the same will be driven by greater awareness of the medical condition. Its symptoms such as cataplexy and hallucinations, which can be life-threatening, have prompted players to invest in drug research and development. Between the forecast year 2021 to 2025, the global Narcolepsy Drugs market is expected to grow at a CAGR of 11.2%, indicating steady growth.

Conclusive Diagnosis of Narcolepsy Manifested by Cataplexy to Lead the Global Narcolepsy Drugs Market

The COVID-19 pandemic has resulted in a range of sleep disorders, highlighting the need to address them to improve daytime wakefulness and productivity. Narcolepsy with Cataplexy or Narcolepsy Type 1 is expected to hold a 68.8% market share in 2021. As the combination of the two ensures conclusive diagnosis, the segment is expected to lead the way in the global narcolepsy drugs market. The report states that despite treatment for narcolepsy, patients may develop cataplexy in later stages. According to the National Sleep Foundation, more than 60% of narcoleptic patients suffer from narcolepsy type 1. Thus, the segment is expected to dominate the global market during the forecast period.

Sodium oxybate will dominate as it remains essential in the management of EDS and cataplexy

The demand for stimulants and selective serotonin to manage narcolepsy will dominate the global narcolepsy drug market. Sodium oxybate, selective serotonin, should lead the way. Its two-pronged approach in the treatment of EDS and cataplexy is driving the growth of this drug segment. According to Narcolepsy UK, it is only licensed to UCB Pharma Ltd., in Europe. Marketed as Xyrem, its application is expected to hold a 52% market share in 2021. It remains an FDA-approved treatment for cataplexy and is best known for enabling patients to have an improved lifestyle while living with the neurological disorder.

Developed regions lead while Youth demographics of Asia-Pacific offers lucrative opportunities

Currently, the global Narcolepsy Drugs market is dominated by developed regions such as Europe and North America. Better awareness, better medical care infrastructure and higher health care infrastructure will Europe and North America to stay ahead of other regions. The recent outbreak of the COVID-19 pandemic has highlighted sleep disturbance issues, which are also considered an undercurrent in demand for narcolepsy drugs. the North America The Narcolepsy Drugs Market is expected to grow at a CAGR of 11.3% from 2021 to 2026.

During this time, Asia Pacific will prove to be a lucrative ground for narcolepsy drugs over the forecast period. Rising stress levels, sleep disturbances due to shift work schedules, and a greater reach of medical awareness have sparked interest in this disorder. As the younger population finds itself struggling with sleep issues, it is expected to highlight the often missed narcolepsy in young patients. Populous economies such as India, Chinaand Japan are expected to be booming markets for Narcolepsy Drugs between the forecast year 2021 to 2025.

Some of the major players operating in the global narcolepsy drugs market are Addrenex Pharmaceuticals, Ligand Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Shire Plc, Arena Pharmaceuticals, Bioproject, Jazz Pharmaceuticals Plc. and Graymark Healthcare, Inc.

Main topics covered:

1. Summary

2. Market Overview
2.1. Market definitions and segmentations
2.2. Market dynamics
2.2.1. Market factors
2.2.2. Market constraints
2.2.3. Market opportunities
2.3. Narcolepsy Drug Pipeline Analysis

3. Global Narcolepsy Drugs Market Outlook, 2018 – 2026
3.1. Global Narcolepsy Drugs Market Outlook, By Therapeutics, 2018 – 2026
3.1.1. Highlights
3.1.2. Global Narcolepsy Drugs Market Outlook, By Therapeutics, Value (Million US$), 2018-2026
3.1.2.1. Psychostimulants
3.1.2.2. Tricyclic antidepressants
3.1.2.3. Sodium Oxybate
3.1.2.4. Selective serotonin reuptake inhibitor
3.1.2.5. Others
3.1.3. Global Narcolepsy Drugs Market Share and BPS Analysis, By Therapeutics, 2021 & 2026
3.1.4. Global Narcolepsy Drugs Market Attractiveness Analysis, By Therapeutics, 2021-2026
3.2. Global Narcolepsy Drugs Market Outlook, By Narcolepsy Type, 2018 – 2026
3.2.1. Highlights
3.2.2. Global Narcolepsy Drugs Market Outlook, By Narcolepsy Type, Value (Million US$), 2018-2026
3.2.2.1. Cataplexy
3.2.2.2. Without cataplexy
3.2.3. Global Narcolepsy Drugs Market Share and BPS Analysis, by Narcolepsy Type, 2021 & 2026
3.2.4. Global Narcolepsy Drugs Market Attractiveness Analysis, By Narcolepsy Type, 2021-2026
3.3. Global Narcolepsy Drugs Market Outlook, By Region, 2018 – 2026
3.3.1. Highlights
3.3.2. Global Narcolepsy Drugs Market Outlook, by Region, Value (Million US$), 2018-2026
3.3.2.1. North America
3.3.2.2. Europe
3.3.2.3. Asia Pacific
3.3.2.4. Rest of the world
3.3.3. Global Narcolepsy Drugs Market Share and BPS Analysis, by Region, 2021 & 2026
3.3.4. Global Narcolepsy Drugs Market Attractiveness Analysis, By Region, 2021-2026

4. North America Narcolepsy Drugs Market Outlook, 2018- 2026

5. Europe Narcolepsy Drugs Market Outlook, 2018- 2026

6. Asia-Pacific Narcolepsy Drugs Market Outlook, 2018- 2026

7. Global Narcolepsy Drugs Market Outlook, 2018- 2026

8. Competitive landscape
8.1. Market share analysis, 2021
8.2. Company Profiles
8.2.1. Jazz Pharmaceuticals, Inc.
8.2.1.1. Company presentation
8.2.1.2. Financial performance
8.2.1.3. Product pipeline
8.2.1.4. RECENT DEVELOPMENTS
8.2.2. Harmony Biosciences
8.2.3. Avadel Pharmaceuticals plc
8.2.4. Axsome Therapeutics, Inc.
8.2.5. Arena Pharmaceuticals, Inc.
8.2.6. Graymark Healthcare, Inc.
8.2.7. Teva Pharmaceutical Industries Ltd.
8.2.8. Shionogi Inc.
8.2.9. Ligand Pharmaceuticals, Inc.

9. Appendix

For more information on this report visit https://www.researchandmarkets.com/r/i4xcdz

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

SOURCE Research and Markets

Comments are closed.